CAJ | 학술논문

目的评价多西紫杉醇、卡培他滨和顺铂(TXP)联合化疗方案对转移性鼻咽癌的疗效及其毒性.方法我们对22名转移性鼻咽癌进行了回顾性研究.所有患者接受21 d为一周期的方案:第1天静脉滴注多西紫杉醇60 mg/m2、第1～14天口服卡培他滨1 250 mg/m2,第1～3天静脉滴注顺铂20 mg/m2.结果在这些患者中,14(63%)例获得部分缓解,2(9%)例获得完全缓解,5(23%)病情稳定.该组患者中总有效率为72%,1年生存率为68%,无进展生存期和总生存期分别为8个月和14个月.主要毒付作用为骨髓抑制,7(32%)例患者经历3/4级粒细胞缺乏症,5(23%)例患者出现3/4级贫血;其他毒付反应均可耐受或可逆.结论 TXP方案是一个安全和有效的转移性鼻咽癌治疗方案,本研究结果与近期文献结果有可比性.
목적 평개다서자삼순、잡배타빈화순박(TXP)연합화료방안대전이성비인암적료효급기독성.방법 아문대22명전이성비인암진행료회고성연구.소유환자접수21 d위일주기적방안:제1천정맥적주다서자삼순60 mg/m2、제1～14천구복잡배타빈1 250 mg/m2,제1～3천정맥적주순박20 mg/m2.결과 재저사환자중,14(63%)례획득부분완해,2(9%)례획득완전완해,5(23%)병정은정.해조환자중총유효솔위72%,1년생존솔위68%,무진전생존기화총생존기분별위8개월화14개월.주요독부작용위골수억제,7(32%)례환자경력3/4급립세포결핍증,5(23%)례환자출현3/4급빈혈;기타독부반응균가내수혹가역.결론 TXP방안시일개안전화유효적전이성비인암치료방안,본연구결과여근기문헌결과유가비성.
Objective To evaluate the efficacy and toxicity of the combined chemotherapy with docetaxel,capecitabine and cisplatin (TXP)in the treatment of metastatic nasopharyngeal carcinoma(NPC).Methods This retrospective analysis involved 22 patients with metastatic NPC receiving treatment with the TXP regimen.The patients were given docetaxel at 60 mg/m2 on day 1,cisplatin at 20 mg/m2 on days 1-3,and capecitabine at 1 250 mg/m2 on days 1-14,and the treatment cycle was repeated ever 3 weeks.Results Of the 22 patients,14(63%)achieved partial remission,2(9%)had complete remission,and 5(23%)showed stable disease.The overall clinical response rate of the patients was 72% with a 1-year survival rate of 68%,median progression-free survival of 8 months,and overall survival of 14 months.The main toxicity was myelosuppression;7(32%)patients experienced grade 3/4 neutropenia,and 5 (23%)had grade 3/4 anemia.All the other adverse effects were tolerable and reversible.Conclusion The TXP regimen is safe and effective for treatment of metastatic NPC,and the results are comparable with those of the reports in recent literatures.